Aclarion, Inc. has announced a significant milestone in the clinical application of its Nociscan technology, as demonstrated by Mr. John Sutcliffe, Lead Clinician at The London Spine Clinic. In a recent video, Sutcliffe discusses his experience with nearly 100 Nociscans performed at The London Clinic, emphasizing the tool’s role in evaluating chronic low back pain. Nociscan utilizes magnetic resonance spectroscopy (MRS) and proprietary signal processing to differentiate between painful and non-painful lumbar discs, providing an objective layer of data that enhances clinical decision-making.

The integration of Nociscan into routine clinical practice at a leading institution underscores its therapeutic potential. Chronic low back pain affects approximately 266 million people globally, and Nociscan has shown to significantly improve surgical outcomes, with a reported 97% success rate when all Nociscan-positive discs are treated. This advancement not only aids in precise diagnosis but also optimizes treatment strategies, potentially reducing unnecessary surgeries and improving patient quality of life.

The growing adoption of Nociscan could shift current paradigms in pain management and spinal health. As more clinicians incorporate this technology into their practice, it may accelerate the development of biomarker-driven therapies and refine diagnostic protocols for chronic low back pain. This evolution in clinical practice highlights the importance of leveraging advanced technologies in addressing complex health challenges, paving the way for more personalized and effective treatment options in the future.

Source: globenewswire.com